

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
27 March 2025 (27.03.2025)



(10) International Publication Number  
**WO 2025/064449 A1**

(51) International Patent Classification:

A61K 9/00 (2006.01) A61K 47/10 (2017.01)  
A61K 9/10 (2006.01) A61K 47/14 (2017.01)  
A61K 31/341 (2006.01) A61K 47/26 (2006.01)

(21) International Application Number:

PCT/US2024/047125

(22) International Filing Date:

17 September 2024 (17.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/583,467 18 September 2023 (18.09.2023) US

(71) Applicant: **EIRION THERAPEUTICS, INC.** [US/US];  
25-K Olympia Ave., Suite 200, Woburn, Massachusetts  
01801 (US).

(72) Inventors: **EDELSON, Jonathan**; c/o Eirion Therapeu-  
tics, Inc., 25-K Olympia Ave., Suite 200, Woburn, Massa-  
chusetts 01801 (US). **HAMMER, James D.**; c/o Pharma-

sol Corporation, 1 Norfolk Avenue, Easton, Massachusetts  
02375 (US).

(74) Agent: **SUBRAMANIAN, Sowmya** et al.; CHOATE,  
HALL & STEWART LLP, Two International Place, Boston,  
Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,  
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,  
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,  
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,  
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,  
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,  
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, CV,  
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,  
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,  
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: TOPICAL COMPOSITIONS AND USES OF PAI-1 INHIBITORS




FIG. 1

(57) Abstract: The present disclosure provides new technologies (e.g., compositions) and their methods of use. Among other things, the present disclosure provides an insight that improved compositions, for example of plasminogen activator inhibitor -1 (PAI-1) inhibitors, may be useful in the treatment and/or prevention of certain diseases, disorders, and/or conditions.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,  
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,  
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *as to applicant's entitlement to apply for and be granted a  
patent (Rule 4.17(ii))*

**Published:**

— *with international search report (Art. 21(3))*